Roghayeh Sheervalilou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roghayeh Sheervalilou has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
Milad Shirvaliloo
Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
13 shared publications- Saman Sargazi
Cellular and Molecular Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan 9816743463, Iran
9 shared publications Habib Ghaznavi
Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
6 shared publicationsSaman Sargazi
Cellular and Molecular Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, Iran
6 shared publicationsOmolbanin Shahraki
Pharmacology Research Center Zahedan University of Medical Sciences Zahedan Iran
5 shared publications- Habib Ghaznavi
Department of Pharmacology, Zahedan University of Medical Sciences, Zahedan, Iran
4 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Integrated in vitro and bioinformatic analysis of autophagy‑related gene expression modulated by Fe₂O₃/Au core–shell nanoparticles in breast cancer cells
Nanomaterials (NMs) with tunable physicochemical and redox properties offer powerful tools for probing cellular regulatory pathways. Accumulating evidence suggests that nanoparticles (NPs) exposure can engage autophagy, a conserved lysosome‑dependent stress‑adaptation process. In this context, iron oxide-gold core-shell nanoparticles (Fe₂O₃/Au NPs) provide a rational platform to investigate nanoparticle‑mediated modulation of autophagy‑related gene (ATG) expression in cancer cells. MCF-7 breast cancer cells and human umbilical vein endothelial cells (HUVECs) were cultured under standard conditions and treated with Fe₂O₃/Au core-shell NPs (20 µg/mL). Nanoparticle uptake was quantified by inductively coupled plasma mass spectrometry (ICP-MS). Gene expression of Beclin1 (BECN1), autophagy-related gene 5 (ATG5), autophagy-related protein light chain 3 (LC3-II), Sequestosome 1 (SQSTM1 or p62), and NBR1 was measured using quantitative polymerase chain reaction (RT-qPCR), normalized to Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and analyzed via the 2-ΔΔCt method. Statistical analyses were conducted with GraphPad Prism 6, with significance set at p < 0.05. Bioinformatics validation was performed using Gene Expression Omnibus (GEO) dataset GSE116436, focusing on five ATGs. ICP-MS confirmed efficient nanoparticle internalization, with higher uptake in MCF-7 cells than in HUVECs. In MCF-7 cells, Fe₂O₃/Au NPs significantly upregulated BECN1, ATG5, and LC3-II, while p62 and NBR1 were downregulated (p < 0.05), indicating considerable autophagy activation and enhanced without direct flux validation. In contrast, HUVECs showed only mild, non-significant changes, consistent with partial or protective autophagy (p > 0.05). Bioinformatic analysis of the GEO dataset GSE116436 confirmed significant dysregulation of five core ATGs (BECN1, ATG5, SQSTM1/p62, NBR1, and MAP1LC3B) in chemotherapy‑resistant MCF‑7 cells, with BECN1 and ATG5 showing the strongest statistical significance. Gene ontology/ Kyoto Encyclopedia of Genes and Genomes (GO/KEGG) enrichment indicated involvement of autophagy, mechanistic target of rapamycin (mTOR), p53, and stress‑response pathways. Kaplan-Meier (KM) survival analysis in the Cancer Genome Atlas-breast cancer (TCGA‑BRCA) cohort revealed gene‑specific, heterogeneous prognostic associations higher BECN1 and NBR1 linked to improved survival, while elevated ATG5 and SQSTM1 correlated with poorer outcomes. STRING‑based protein-protein interaction (PPI) analysis highlighted enrichment of growth factor signaling, extracellular matrix (ECM) organization, and focal adhesion networks, supporting functional coordination among dysregulated genes and associated stromal‑adaptive signaling modules. Fe₂O₃/Au core-shell NPs selectively altered the transcription of key ATGs in MCF‑7 breast cancer cells, with minimal effects in non‑malignant HUVECs. Bioinformatic analyses in chemotherapy‑resistant MCF‑7 models confirmed persistent dysregulation of the same ATGs and enrichment of stress‑adaptive pathways. Collectively, these findings indicate a cancer‑selective, autophagy‑associated transcriptional response and support a hypothesis‑generating link to adaptive features of resistant breast cancer cells.
- 29 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessIntegrated in vitro and bioinformatic analysis of autophagy‑related gene expression modulated by Fe₂O₃/Au core–shell nanoparticles in breast cancer cells
Nanomaterials (NMs) with tunable physicochemical and redox properties offer powerful tools for probing cellular regulatory pathways. Accumulating evidence suggests that nanoparticles (NPs) exposure can engage autophagy, a conserved lysosome‑dependent stress‑adaptation process. In this context, iron oxide-gold core-shell nanoparticles (Fe₂O₃/Au NPs) provide a rational platform to investigate nanoparticle‑mediated modulation of autophagy‑related gene (ATG) expression in cancer cells. MCF-7 breast cancer cells and human umbilical vein endothelial cells (HUVECs) were cultured under standard conditions and treated with Fe₂O₃/Au core-shell NPs (20 µg/mL). Nanoparticle uptake was quantified by inductively coupled plasma mass spectrometry (ICP-MS). Gene expression of Beclin1 (BECN1), autophagy-related gene 5 (ATG5), autophagy-related protein light chain 3 (LC3-II), Sequestosome 1 (SQSTM1 or p62), and NBR1 was measured using quantitative polymerase chain reaction (RT-qPCR), normalized to Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and analyzed via the 2-ΔΔCt method. Statistical analyses were conducted with GraphPad Prism 6, with significance set at p < 0.05. Bioinformatics validation was performed using Gene Expression Omnibus (GEO) dataset GSE116436, focusing on five ATGs. ICP-MS confirmed efficient nanoparticle internalization, with higher uptake in MCF-7 cells than in HUVECs. In MCF-7 cells, Fe₂O₃/Au NPs significantly upregulated BECN1, ATG5, and LC3-II, while p62 and NBR1 were downregulated (p < 0.05), indicating considerable autophagy activation and enhanced without direct flux validation. In contrast, HUVECs showed only mild, non-significant changes, consistent with partial or protective autophagy (p > 0.05). Bioinformatic analysis of the GEO dataset GSE116436 confirmed significant dysregulation of five core ATGs (BECN1, ATG5, SQSTM1/p62, NBR1, and MAP1LC3B) in chemotherapy‑resistant MCF‑7 cells, with BECN1 and ATG5 showing the strongest statistical significance. Gene ontology/ Kyoto Encyclopedia of Genes and Genomes (GO/KEGG) enrichment indicated involvement of autophagy, mechanistic target of rapamycin (mTOR), p53, and stress‑response pathways. Kaplan-Meier (KM) survival analysis in the Cancer Genome Atlas-breast cancer (TCGA‑BRCA) cohort revealed gene‑specific, heterogeneous prognostic associations higher BECN1 and NBR1 linked to improved survival, while elevated ATG5 and SQSTM1 correlated with poorer outcomes. STRING‑based protein-protein interaction (PPI) analysis highlighted enrichment of growth factor signaling, extracellular matrix (ECM) organization, and focal adhesion networks, supporting functional coordination among dysregulated genes and associated stromal‑adaptive signaling modules. Fe₂O₃/Au core-shell NPs selectively altered the transcription of key ATGs in MCF‑7 breast cancer cells, with minimal effects in non‑malignant HUVECs. Bioinformatic analyses in chemotherapy‑resistant MCF‑7 models confirmed persistent dysregulation of the same ATGs and enrichment of stress‑adaptive pathways. Collectively, these findings indicate a cancer‑selective, autophagy‑associated transcriptional response and support a hypothesis‑generating link to adaptive features of resistant breast cancer cells.
- 31 December 2025
- Published by Elsevier in Brain Research
- Vol. 1874, 150137
Identification of hub genes and signaling pathways as possible therapeutic targets in human glioblastoma: evidenced by bioinformatics analysis
- 31 December 2025
- Published by Elsevier in Brain Research
- Vol. 1874, 150137
Identification of hub genes and signaling pathways as possible therapeutic targets in human glioblastoma: evidenced by bioinformatics analysis
- Open Access
- 7 May 2025
- Published by Qeios Ltd
Review of: "Investigating Alzheimer's Disease-Associated Genes Using Differential Splicing Frequency Analysis"
It's an interesting study and has considerable results. The researchers used differential splicing frequency analysis (DSFA), which enables more sensitive capture of the alternative splicing information in RNA-seq data. There are some minor concerns;...
- 7 May 2025
- Published by Qeios Ltd
Open AccessReview of: "Investigating Alzheimer's Disease-Associated Genes Using Differential Splicing Frequency Analysis"
It's an interesting study and has considerable results. The researchers used differential splicing frequency analysis (DSFA), which enables more sensitive capture of the alternative splicing information in RNA-seq data. There are some minor concerns;...
- Open Access
- 8 January 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-14
Synthesis, characterization, and evaluation of copper-doped zinc oxide nanoparticles anticancer effects: in vitro and in vivo experiments
Zinc oxide and copper oxide nanoparticles are known for their promising biological activities. This study aims to synthesize zinc oxide nanoparticles and copper-doped zinc oxide nanoparticles to harness the combined cytotoxic and anticancer effects of them in vitro and in vivo studies. Zinc oxide nanoparticles, both doped and undoped, were synthesized using a chemical co-precipitation method. All synthetized nanoparticles were examined for shape, crystal structure and morphology/ microstructure using X-ray diffractometers, scanning electron microscopy and transmission electron microscopy. The hydrodynamic diameter and zeta-potential was measured by dynamic light scattering. Energy Dispersive Spectroscopy evaluated copper doping in zinc oxide nanoparticles. The anticancer effects were tested on bone cancer fibroblast cells and normal lung fibroblast cells using cell viability test, colony formation assay, and lactate dehydrogenase assay at concentrations of 0, 1, 10, 17.5, 25, 50, 100, and 200 μg/ml. In vivo experiments assessed serum markers (Aspartate aminotransferase, Alanine transaminase, blood urea nitrogen and creatinine) and liver malondialdehyde levels in response to 5 mg/kg and 50 mg/kg doses. zinc oxide nanoparticles exhibited a spherical morphology and good dispersion, with an average grain size ranging from 15–39 nm. Copper-doped zinc oxide nanoparticles displayed a mixture of rod-like and grain-like structures, and a larger average grain size of 18–68 nm. X-ray diffraction analysis confirmed the wurtzite crystal structure for both types of nanoparticles. While individual grain sizes varied, the mean particle size for all samples, including those with increasing copper doping, was approximately 100 ± 0.1 nm. Both nanoparticles exhibited a negative zeta potential. In vitro studies revealed that copper-doped zinc oxide nanoparticles, zinc oxide nanoparticles, and bulk zinc oxide exhibited cytotoxic activity (cell viability < 80%) and induced apoptosis in bone cancer fibroblast cells at 17.5 μg/ml after 72 h (P < 0.05). The copper-doped zinc oxide nanoparticles demonstrated higher cytotoxicity compared to zinc oxide nanoparticles and bulk zinc oxide at higher concentrations (P < 0.05). The copper-doped zinc oxide nanoparticles also showed significant inhibition of cell proliferation over 10 days at 17.5 μg/ml (P < 0.05). In vivo studies indicated no significant changes in serum Aspartate aminotransferase, Alanine transaminase, blood urea nitrogen, and creatinine levels at 5 mg/kg. However, a 50 mg/kg dose of zinc oxide nanoparticles and copper-doped zinc oxide nanoparticles significantly increased these serum markers and liver malondialdehyde levels (P < 0.05). Histological analysis revealed liver injury in rats treated with 50 mg/kg but not at 0.5 mg/kg. The copper-doped zinc oxide nanoparticles exhibit enhanced cytotoxicity and anticancer activity compared to zinc oxide nanoparticles and bulk zinc oxide, particularly at higher concentrations. High doses of these nanoparticles could induce significant biochemical changes and liver injury in vivo, highlighting the need for careful dose management.
- 8 January 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-14
Open AccessSynthesis, characterization, and evaluation of copper-doped zinc oxide nanoparticles anticancer effects: in vitro and in vivo experiments
Zinc oxide and copper oxide nanoparticles are known for their promising biological activities. This study aims to synthesize zinc oxide nanoparticles and copper-doped zinc oxide nanoparticles to harness the combined cytotoxic and anticancer effects of them in vitro and in vivo studies. Zinc oxide nanoparticles, both doped and undoped, were synthesized using a chemical co-precipitation method. All synthetized nanoparticles were examined for shape, crystal structure and morphology/ microstructure using X-ray diffractometers, scanning electron microscopy and transmission electron microscopy. The hydrodynamic diameter and zeta-potential was measured by dynamic light scattering. Energy Dispersive Spectroscopy evaluated copper doping in zinc oxide nanoparticles. The anticancer effects were tested on bone cancer fibroblast cells and normal lung fibroblast cells using cell viability test, colony formation assay, and lactate dehydrogenase assay at concentrations of 0, 1, 10, 17.5, 25, 50, 100, and 200 μg/ml. In vivo experiments assessed serum markers (Aspartate aminotransferase, Alanine transaminase, blood urea nitrogen and creatinine) and liver malondialdehyde levels in response to 5 mg/kg and 50 mg/kg doses. zinc oxide nanoparticles exhibited a spherical morphology and good dispersion, with an average grain size ranging from 15–39 nm. Copper-doped zinc oxide nanoparticles displayed a mixture of rod-like and grain-like structures, and a larger average grain size of 18–68 nm. X-ray diffraction analysis confirmed the wurtzite crystal structure for both types of nanoparticles. While individual grain sizes varied, the mean particle size for all samples, including those with increasing copper doping, was approximately 100 ± 0.1 nm. Both nanoparticles exhibited a negative zeta potential. In vitro studies revealed that copper-doped zinc oxide nanoparticles, zinc oxide nanoparticles, and bulk zinc oxide exhibited cytotoxic activity (cell viability < 80%) and induced apoptosis in bone cancer fibroblast cells at 17.5 μg/ml after 72 h (P < 0.05). The copper-doped zinc oxide nanoparticles demonstrated higher cytotoxicity compared to zinc oxide nanoparticles and bulk zinc oxide at higher concentrations (P < 0.05). The copper-doped zinc oxide nanoparticles also showed significant inhibition of cell proliferation over 10 days at 17.5 μg/ml (P < 0.05). In vivo studies indicated no significant changes in serum Aspartate aminotransferase, Alanine transaminase, blood urea nitrogen, and creatinine levels at 5 mg/kg. However, a 50 mg/kg dose of zinc oxide nanoparticles and copper-doped zinc oxide nanoparticles significantly increased these serum markers and liver malondialdehyde levels (P < 0.05). Histological analysis revealed liver injury in rats treated with 50 mg/kg but not at 0.5 mg/kg. The copper-doped zinc oxide nanoparticles exhibit enhanced cytotoxicity and anticancer activity compared to zinc oxide nanoparticles and bulk zinc oxide, particularly at higher concentrations. High doses of these nanoparticles could induce significant biochemical changes and liver injury in vivo, highlighting the need for careful dose management.
- 29 October 2024
- Published by Springer Nature in Medical Oncology
- Vol. 41 (12) , 1-19
Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery
Glioblastoma (GBM) is a highly prevalent and aggressive brain tumor in adults with limited treatment response, leading to a 5-year survival rate of less than 5%. Standard therapies, including surgery, radiation, and chemotherapy, often fall short due to the tumor’s location, hypoxic conditions, and the challenge of complete removal. Moreover, brain metastases from cancers such as breast and melanoma carry similarly poor prognoses. Recent advancements in nanomedicine offer promising solutions for targeted GBM therapies, with nanoparticles (NPs) capable of delivering chemotherapy drugs or radiation sensitizers across the blood–brain barrier (BBB) to specific tumor sites. Leveraging the enhanced permeability and retention effect, NPs can preferentially accumulate in tumor tissues, where compromised BBB regions enhance delivery efficiency. By modifying NP characteristics such as size, shape, and surface charge, researchers have improved circulation times and cellular uptake, enhancing therapeutic efficacy. Recent studies show that combining photothermal therapy with magnetic hyperthermia using AuNPs and magnetic NPs induces ROS-dependent apoptosis and immunogenic cell death providing dual-targeted, immune-activating approaches. This review discusses the latest NP-based drug delivery strategies, including gene therapy, receptor-mediated transport, and multi-modal approaches like photothermal-magnetic hyperthermia combinations, all aimed at optimizing therapeutic outcomes for GBM. Graphical Abstract
- 29 October 2024
- Published by Springer Nature in Medical Oncology
- Vol. 41 (12) , 1-19
Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery
Glioblastoma (GBM) is a highly prevalent and aggressive brain tumor in adults with limited treatment response, leading to a 5-year survival rate of less than 5%. Standard therapies, including surgery, radiation, and chemotherapy, often fall short due to the tumor’s location, hypoxic conditions, and the challenge of complete removal. Moreover, brain metastases from cancers such as breast and melanoma carry similarly poor prognoses. Recent advancements in nanomedicine offer promising solutions for targeted GBM therapies, with nanoparticles (NPs) capable of delivering chemotherapy drugs or radiation sensitizers across the blood–brain barrier (BBB) to specific tumor sites. Leveraging the enhanced permeability and retention effect, NPs can preferentially accumulate in tumor tissues, where compromised BBB regions enhance delivery efficiency. By modifying NP characteristics such as size, shape, and surface charge, researchers have improved circulation times and cellular uptake, enhancing therapeutic efficacy. Recent studies show that combining photothermal therapy with magnetic hyperthermia using AuNPs and magnetic NPs induces ROS-dependent apoptosis and immunogenic cell death providing dual-targeted, immune-activating approaches. This review discusses the latest NP-based drug delivery strategies, including gene therapy, receptor-mediated transport, and multi-modal approaches like photothermal-magnetic hyperthermia combinations, all aimed at optimizing therapeutic outcomes for GBM. Graphical Abstract
- Open Access
- 7 May 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-18
New insights into targeted therapy of glioblastoma using smart nanoparticles
In recent times, the intersection of nanotechnology and biomedical research has given rise to nanobiomedicine, a captivating realm that holds immense promise for revolutionizing diagnostic and therapeutic approaches in the field of cancer. This innovative fusion of biology, medicine, and nanotechnology aims to create diagnostic and therapeutic agents with enhanced safety and efficacy, particularly in the realm of theranostics for various malignancies. Diverse inorganic, organic, and hybrid organic–inorganic nanoparticles, each possessing unique properties, have been introduced into this domain. This review seeks to highlight the latest strides in targeted glioblastoma therapy by focusing on the application of inorganic smart nanoparticles. Beyond exploring the general role of nanotechnology in medical applications, this review delves into groundbreaking strategies for glioblastoma treatment, showcasing the potential of smart nanoparticles through in vitro studies, in vivo investigations, and ongoing clinical trials.
- 7 May 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-18
Open AccessNew insights into targeted therapy of glioblastoma using smart nanoparticles
In recent times, the intersection of nanotechnology and biomedical research has given rise to nanobiomedicine, a captivating realm that holds immense promise for revolutionizing diagnostic and therapeutic approaches in the field of cancer. This innovative fusion of biology, medicine, and nanotechnology aims to create diagnostic and therapeutic agents with enhanced safety and efficacy, particularly in the realm of theranostics for various malignancies. Diverse inorganic, organic, and hybrid organic–inorganic nanoparticles, each possessing unique properties, have been introduced into this domain. This review seeks to highlight the latest strides in targeted glioblastoma therapy by focusing on the application of inorganic smart nanoparticles. Beyond exploring the general role of nanotechnology in medical applications, this review delves into groundbreaking strategies for glioblastoma treatment, showcasing the potential of smart nanoparticles through in vitro studies, in vivo investigations, and ongoing clinical trials.
- 24 February 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 98 (2) , 671-689
Identification of microRNA-mRNA Regulatory Networks with Therapeutic Values in Alzheimer’s Disease by Bioinformatics Analysis
Background: Alzheimer’s disease (AD) is the most prevalent neurological disorder worldwide, affecting approximately 24 million individuals. Despite more than a century of research on AD, its pathophysiology is still not fully understood. Objective: Recently, genetic studies of AD have focused on analyzing the general expression profile by employing high-throughput genomic techniques such as microarrays. Current research has leveraged bioinformatics advancements in genetic science to build upon previous efforts. Methods: Data from the GSE118553 dataset used in this investigation, and the analyses carried out using programs such as Limma and BioBase. Differentially expressed genes (DEGs) and differentially expressed microRNAs (DEmiRs) associated with AD identified in the studied areas of the brain. Target genes of the DEmiRs identified using the MultiMiR package. Gene ontology (GO) completed using the Enrichr website, and the protein-protein interaction (PPI) network for these genes drawn using STRING and Cytoscape software. Results: The findings introduced DEGs including CTNNB1, PAK2, MAP2K1, PNPLA6, IGF1R, FOXL2, DKK3, LAMA4, PABPN1, and GDPD5, and DEmiRs linked to AD (miR-106A, miR-1826, miR-1253, miR-10B, miR-18B, miR-101-2, miR-761, miR-199A1, miR-379 and miR-668), (miR-720, miR-218-2, miR-25, miR-602, miR-1226, miR-548K, miR-H1, miR-410, miR-548F2, miR-181A2), (miR-1470, miR-651, miR-544, miR-1826, miR-195, miR-610, miR-599, miR-323, miR-587 and miR-340), and (miR-1282, miR-1914, miR-642, miR-1323, miR-373, miR-323, miR-1322, miR-612, miR-606 and miR-758) in cerebellum, frontal cortex, temporal cortex, and entorhinal cortex, respectively. Conclusions: The majority of the genes and miRNAs identified by our findings may be employed as biomarkers for prediction, diagnosis, or therapy response monitoring.
- 24 February 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 98 (2) , 671-689
Identification of microRNA-mRNA Regulatory Networks with Therapeutic Values in Alzheimer’s Disease by Bioinformatics Analysis
Background: Alzheimer’s disease (AD) is the most prevalent neurological disorder worldwide, affecting approximately 24 million individuals. Despite more than a century of research on AD, its pathophysiology is still not fully understood. Objective: Recently, genetic studies of AD have focused on analyzing the general expression profile by employing high-throughput genomic techniques such as microarrays. Current research has leveraged bioinformatics advancements in genetic science to build upon previous efforts. Methods: Data from the GSE118553 dataset used in this investigation, and the analyses carried out using programs such as Limma and BioBase. Differentially expressed genes (DEGs) and differentially expressed microRNAs (DEmiRs) associated with AD identified in the studied areas of the brain. Target genes of the DEmiRs identified using the MultiMiR package. Gene ontology (GO) completed using the Enrichr website, and the protein-protein interaction (PPI) network for these genes drawn using STRING and Cytoscape software. Results: The findings introduced DEGs including CTNNB1, PAK2, MAP2K1, PNPLA6, IGF1R, FOXL2, DKK3, LAMA4, PABPN1, and GDPD5, and DEmiRs linked to AD (miR-106A, miR-1826, miR-1253, miR-10B, miR-18B, miR-101-2, miR-761, miR-199A1, miR-379 and miR-668), (miR-720, miR-218-2, miR-25, miR-602, miR-1226, miR-548K, miR-H1, miR-410, miR-548F2, miR-181A2), (miR-1470, miR-651, miR-544, miR-1826, miR-195, miR-610, miR-599, miR-323, miR-587 and miR-340), and (miR-1282, miR-1914, miR-642, miR-1323, miR-373, miR-323, miR-1322, miR-612, miR-606 and miR-758) in cerebellum, frontal cortex, temporal cortex, and entorhinal cortex, respectively. Conclusions: The majority of the genes and miRNAs identified by our findings may be employed as biomarkers for prediction, diagnosis, or therapy response monitoring.
- 12 February 2024
- Published by Taylor & Francis in Toxin Reviews
- Vol. 43 (2) , 179-189
Application of nanotechnology in removing laboratory contaminants from the environment
- 12 February 2024
- Published by Taylor & Francis in Toxin Reviews
- Vol. 43 (2) , 179-189
Application of nanotechnology in removing laboratory contaminants from the environment
- 1 February 2024
- Published by Taylor & Francis in Current Eye Research
- Vol. 49 (6) , 551-564
The Traces of Dysregulated lncRNAs-Associated ceRNA Axes in Retinoblastoma: A Systematic Scope Review
Long non-coding RNAs are an essential component of competing endogenous RNA regulatory axes and play their role by sponging microRNAs and interfering with the regulation of gene expression. Because of the broadness of competing endogenous RNA interaction networks, they may help investigate treatment targets in complicated disorders. This study performed a systematic scoping review to assess verified loops of competing endogenous RNAs in retinoblastoma, emphasizing the competing endogenous RNAs axis related to long non-coding RNAs. We used a six-stage approach framework and the PRISMA guidelines. A systematic search of seven databases was done to locate suitable papers published before February 2022. Two reviewers worked independently to screen articles and collect data. Out of 363 records, fifty-one articles met the inclusion criteria, and sixty-three axes were identified in desired articles. The majority of the research reported several long non-coding RNAs that were experimentally verified to act as competing endogenous RNAs in retinoblastoma: XIST/NEAT1/MALAT1/SNHG16/KCNQ1OT1, respectively. At the same time, around half of the studies investigated unique long non-coding RNAs. Understanding the many features of this regulatory system may aid in elucidating the unknown etiology of Retinoblastoma and providing novel molecular targets for therapeutic and clinical applications.
- 1 February 2024
- Published by Taylor & Francis in Current Eye Research
- Vol. 49 (6) , 551-564
The Traces of Dysregulated lncRNAs-Associated ceRNA Axes in Retinoblastoma: A Systematic Scope Review
Long non-coding RNAs are an essential component of competing endogenous RNA regulatory axes and play their role by sponging microRNAs and interfering with the regulation of gene expression. Because of the broadness of competing endogenous RNA interaction networks, they may help investigate treatment targets in complicated disorders. This study performed a systematic scoping review to assess verified loops of competing endogenous RNAs in retinoblastoma, emphasizing the competing endogenous RNAs axis related to long non-coding RNAs. We used a six-stage approach framework and the PRISMA guidelines. A systematic search of seven databases was done to locate suitable papers published before February 2022. Two reviewers worked independently to screen articles and collect data. Out of 363 records, fifty-one articles met the inclusion criteria, and sixty-three axes were identified in desired articles. The majority of the research reported several long non-coding RNAs that were experimentally verified to act as competing endogenous RNAs in retinoblastoma: XIST/NEAT1/MALAT1/SNHG16/KCNQ1OT1, respectively. At the same time, around half of the studies investigated unique long non-coding RNAs. Understanding the many features of this regulatory system may aid in elucidating the unknown etiology of Retinoblastoma and providing novel molecular targets for therapeutic and clinical applications.
- Open Access
- 1 December 2023
- Published by Springer Nature in BMC Medical Genomics
- Vol. 16 (1) , 1-15
Identification of differentially expressed genes associated with the pathogenesis of gastric cancer by bioinformatics analysis
Aim: Gastric cancer (GC) is one of the most diagnosed cancers worldwide. GC is a heterogeneous disease whose pathogenesis has not been entirely understood. Besides, the GC prognosis for patients remains poor. Hence, finding reliable biomarkers and therapeutic targets for GC patients is urgently needed. Methods: GSE54129 and GSE26942 datasets were downloaded from Gene Expression Omnibus (GEO) database to detect differentially expressed genes (DEGs). Then, gene set enrichment analyses and protein-protein interactions were investigated. Afterward, ten hub genes were identified from the constructed network of DEGs. Then, the expression of hub genes in GC was validated. Performing survival analysis, the prognostic value of each hub gene in GC samples was investigated. Finally, the databases were used to predict microRNAs that could regulate the hub genes. Eventually, top miRNAs with more interactions with the list of hub genes were introduced. Results: In total, 203 overlapping DEGs were identified between both datasets. The main enriched KEGG pathway was “Protein digestion and absorption.” The most significant identified GO terms included “primary alcohol metabolic process,” “basal part of cell,” and “extracellular matrix structural constituent conferring tensile strength.” Identified hub modules were COL1A1, COL1A2, TIMP1, SPP1, COL5A2, THBS2, COL4A1, MUC6, CXCL8, and BGN. The overexpression of seven hub genes was associated with overall survival. Moreover, among the list of selected miRNAs, hsa-miR-27a-3, hsa-miR-941, hsa-miR-129-2-3p, and hsa-miR-1-3p, were introduced as top miRNAs targeting more than five hub genes. Conclusions: The present study identified ten genes associated with GC, which may help discover novel prognostic and diagnostic biomarkers as well as therapeutic targets for GC. Our results may advance the understanding of GC occurrence and progression.
- 1 December 2023
- Published by Springer Nature in BMC Medical Genomics
- Vol. 16 (1) , 1-15
Open AccessIdentification of differentially expressed genes associated with the pathogenesis of gastric cancer by bioinformatics analysis
Aim: Gastric cancer (GC) is one of the most diagnosed cancers worldwide. GC is a heterogeneous disease whose pathogenesis has not been entirely understood. Besides, the GC prognosis for patients remains poor. Hence, finding reliable biomarkers and therapeutic targets for GC patients is urgently needed. Methods: GSE54129 and GSE26942 datasets were downloaded from Gene Expression Omnibus (GEO) database to detect differentially expressed genes (DEGs). Then, gene set enrichment analyses and protein-protein interactions were investigated. Afterward, ten hub genes were identified from the constructed network of DEGs. Then, the expression of hub genes in GC was validated. Performing survival analysis, the prognostic value of each hub gene in GC samples was investigated. Finally, the databases were used to predict microRNAs that could regulate the hub genes. Eventually, top miRNAs with more interactions with the list of hub genes were introduced. Results: In total, 203 overlapping DEGs were identified between both datasets. The main enriched KEGG pathway was “Protein digestion and absorption.” The most significant identified GO terms included “primary alcohol metabolic process,” “basal part of cell,” and “extracellular matrix structural constituent conferring tensile strength.” Identified hub modules were COL1A1, COL1A2, TIMP1, SPP1, COL5A2, THBS2, COL4A1, MUC6, CXCL8, and BGN. The overexpression of seven hub genes was associated with overall survival. Moreover, among the list of selected miRNAs, hsa-miR-27a-3, hsa-miR-941, hsa-miR-129-2-3p, and hsa-miR-1-3p, were introduced as top miRNAs targeting more than five hub genes. Conclusions: The present study identified ten genes associated with GC, which may help discover novel prognostic and diagnostic biomarkers as well as therapeutic targets for GC. Our results may advance the understanding of GC occurrence and progression.